Our Management Team is One of the Most Experienced
in the Biotech Industry

Edward Lanphier, the founder of Sangamo BioSciences, Inc., has served as President, Chief Executive Officer and as a member of the Board of Directors since Sangamo's inception in 1995. Mr. Lanphier has over twenty-five years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, he was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he served as Vice President of Corporate Development at Biotherapeutics, Inc. From 1984 to 1986 Mr. Lanphier served as Vice President of Corporate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute. Mr. Lanphier holds a B.A. in biochemistry from Knox College.

Dale Ando, M.D. has served as Vice President, Therapeutic Development and Chief Medical Officer since August 2004. Dr. Ando has held senior positions in therapeutic product development in several biotechnology companies most recently as Vice President, Clinical Research at Cell Genesys, Inc. While at Cell Genesys, Dr. Ando directed the development of Phase I-III GVAX programs, oncolytic virus programs and Phase I/II trials of chimaeric T-cell receptor products in HIV and cancer. Prior to joining Cell Genesys in 1997, Dr. Ando spent six years at Chiron Corporation as director of clinical gene therapy and three years at Cetus Corporation. From 1997 to 2001 Dr. Ando served as a member of the Recombinant DNA Advisory Committee (RAC) and the Adenoviral Safety Committee for the National Institutes of Health (NIH). Dr. Ando began his career as a faculty member at UCLA Medical School in the Division of Rheumatology. He received his M.D. and Internal Medicine training at the University of Michigan and a B.S. in Chemistry from Stanford University. Dr. Ando is board certified in internal medicine and is a subspecialist in Rheumatology.

Philip D. Gregory, D. Phil. has served as Chief Scientific Officer since July 2009 and Vice President, Research since October 2005. He joined Sangamo in December 2000 as a Scientist, became a Team Leader in October 2001, Senior Director, Research in July 2003 and Vice President, Research in October 2005. Prior to joining the company, Dr. Gregory was at the University of Munich, Germany, where he studied the role of chromatin structure in gene regulation and published extensively in this field. He has served as a member of the Scientific Advisory Board of Keystone Symposia since December 2009. Dr. Gregory earned a D. Phil. In Biochemistry from the University of Oxford and holds a B.Sc. in microbiology from the University of Sheffield.

David G. Ichikawa has served as Senior Vice President, Business Development since December 2004. Prior to joining Sangamo, Mr. Ichikawa was most recently Chief Business Officer for Sagres Discovery, where he was responsible for corporate strategy and business development activities. While at Sagres he negotiated a major collaboration with Boehringer Ingelheim, the strategic acquisition of MemRx Corporation and played a critical role in the acquisition of Sagres by Chiron Corporation. Prior to Sagres Discovery, David held several positions with Chiron Corporation including Vice President, R&D Business Development and Finance. Mr. Ichikawa earned his M.B.A. degree from the University of California at Berkeley and a B.S. degree from the University of California at Davis.

Ely Benaim, M.D. has served as Vice President, Clinical Affairs since April 2007. Dr. Benaim has twenty years of experience in the medical field including ten years of clinical research experience in academia, government and the biotechnology and pharmaceutical industries. He most recently served as Global Development Leader, Global Clinical Development at Amgen, Inc. While at Amgen, Dr. Benaim oversaw the clinical development of multiple of oncology therapeutic drug candidates. Prior to joining Amgen in 2005, Dr. Benaim served as Global Senior Director, Oncology Clinical Development at Salmedix Inc. (now Cephalon, Inc.) where he led the development of TREANDA(R) (Bendamustine HCl) to a Phase 3 pivotal trial for lymphoma. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude's Children's Research Hospital, Memphis, Tennessee. From 1997 to 2004, he was Assistant Professor in the Department of Pediatrics at the University of Tennessee and an Assistant Member to the Department of Hematology/Oncology. As a member of the Transplantation and Gene Therapy program he published several manuscripts on the areas of stem cell transplantation, immunology and gene therapy.

Shirley Clift has served as Vice President,, Regulatory Affairs since January 2010. Ms. Clift has more than fifteen years of biotechnology management experience in global regulatory affairs and cellular and gene therapy product development. Prior to joining Sangamo, from 1997 to 2009, she worked for Cell Genesys, Inc., a biotechnology company primarily focused on development and commercialization of novel immunotherapeutic products for multiple indications in cancer. At Cell Genesys, Ms. Clift held various positions in regulatory affairs and project management most recently serving as Vice President, Regulatory Affairs. She coordinated and implemented the regulatory strategy for GVAX cellular immunotherapy in advanced prostate cancer including the launch and conduct of two Phase 3 studies in the USA and multiple trials in Europe and Canada and coordinated the regulatory protocols for several other cancer immunotherapy programs. From 1991 to 1997, she managed collaborations and the oncology program at Somatix Therapy Corporation. Ms. Clift holds a Bachelor of Arts from the University of California, Berkeley.

Martin Giedlin, Ph.D. has served as Vice President, Development since February 2008. Dr. Giedlin has over fifteen years of biologic drug development experience at several biotechnology companies most recently as Senior Director, In Vivo Biology at Cerus Corporation where he was responsible for design and implementation of IND-enabling animal studies in support of immunotherapies for the treatment of cancer and infectious disease. Prior to joining Cerus in 2002, he was Director, Pharmacology and Toxicology for Onyx Pharmaceuticals, Inc. from 2000 until 2002. From 1992 to 2002 he was Associate Director, Vaccines and Gene Therapy with Chiron Corporation and prior to that, from 1986 to 1992, was a Research Scientist with Berlex BioSciences, Inc. Dr. Giedlin earned a Ph.D. in Microbiology from the Medical College of Virgina and a B.S. in Biology/Chemistry from the University of Notre Dame.

Ed Rebar, Ph.D. has served as Vice President, Technology since December 2007. He joined Sangamo in August 1998 as a Scientist, became a Team Leader in October 2001 and Senior Director, Technology in November 2003. Prior to joining Sangamo, he was a post-doctoral fellow at University of California, Berkeley. Dr. Rebar earned a Ph.D. from the Massachusetts Institute of Technology, where he developed phage display methods for engineering zinc fingers with novel DNA-binding specificities. Dr. Rebar has authored numerous publications and patents relating to the design and application of zinc finger proteins. He holds a B.S. in Biochemistry from Rutgers University.

Winson Tang, M.D.. has served as Vice President, Clinical Research since January 2010. Dr. Tang has extensive international industry experience in the clinical management and drug development of multiple therapeutic technologies including recombinant proteins, small molecules, anti-sense and gene therapy for diabetes, inflammation, nephrology and antivirals. He has held senior clinical management positions with biotechnology companies including Isis Pharmaceuticals Inc., Tularik Incorporated, Vertex Pharmaceuticals and Amgen Inc. Most recently, from 2008 until 2009, he served as Medical Consultant to Amsterdam Molecular Therapeutics, BV , a gene therapy company focused on monogenic orphan diseases. Dr. Tang received his M.D. at Albert Einstein College of Medicine, and graduated Magna Cum Laude with a combined B.S. /M.S in Chemistry from Tufts University. Dr. Tang is Board Certified in Internal Medicine and is a Fellow of the American College of Physicians.

Greg Zante, CPA, has served as Vice President, Finance and Administration since September 2006. He joined Sangamo as Senior Director, Finance and Administration in August 2003. Prior to joining Sangamo, Mr. Zante was Director, Finance and Administration of Calyx Therapeutics, Inc. a privately held pharmaceutical discovery and development company, from December 2001. From October 1993 until December 2001, Mr. Zante held senior financial managerial positions in several companies including Matrix Pharmaceuticals, Inc. He was employed by Ernst and Young, LLP as a Senior Staff Accountant from October 1993 until November 1995. Mr. Zante holds a B.A. in business-economics and managerial accounting from UCLA and is a Certified Public Accountant in the state of California.

Board of Directors

Paul B. Cleveland. has served as a member of our Board of Directors since November 2008. Mr. Cleveland is currently Executive VicePresident, Corporate Development and Chief Financial Officer for Affymax. From April 2004 to December 2005, he served as a managing director at Integrated Finance, Ltd., an investment bank. From September 1996 to April 2003, he served as a managing director at J.P. Morgan Chase and Co. (and a predecessor firm, Hambrecht & Quist), an investment bank. From January 1993 to September 1996, he was a partner at Cooley Godward LLP, a law firm. From December 1988 to December 1992, he was a corporate attorney at Sidley Austin LLP, a law firm, and from September 1981 to November 1988, he was a corporate attorney at Davis Polk & Wardwell, a law firm. Mr. Cleveland serves as a member of the board of directors and is chairman of the audit committee of Anacor Pharmaceuticals, Inc. Mr. Cleveland holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.

Stephen G. Dilly, M.B.B.S., Ph.D.,. has served as a member of our Board of Directors since March 2010. Since 2006, Dr. Dilly has served as President and Chief Executive Officer and a member of the Board of Directors of APT Pharmaceuticals, Inc., a specialty drug company focused on the development of inhaled cyclosporine for the prevention and treatment of chronic rejection in lung transplantation. From 2003 to 2006, he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003, he held various management positions at Genentech Inc., including Vice President of Development Sciences from 2002 to 2003. From 1988 to 1998, Dr. Dilly held various management positions in drug development with SmithKline Beecham in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly currently serves as a member of the Advisory Board of Physic Ventures and the National Board of Advisors of the UC Davis Health System. In 1982, Dr. Dilly earned his M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and received his Ph.D. in Cardiac Physiology from University of London in 1988.

William G. Gerber, M.D. has served as a member of our Board of Directors since June 1997. Dr. Gerber is currently a partner at Bay City Capital, a life sciences investment fund management firm. From  September 1999 until its merger into Nanogen, Inc. in December 2004, Dr. Gerber was President, Chief Executive Officer and a Director of Epoch Biosciences, Inc., a biomedical company. From April 1998 to July 1999, he was President of diaDexus LLC, a pharmacogenomics company. Previous to his appointment at diaDexus, he was Chief Operating Officer of Onyx Pharmaceuticals. Before joining Onyx in 1995, Dr. Gerber was with Chiron Corporation, a biopharmaceutical, vaccine and blood testing company, where he was President of the Chiron Diagnostics business unit after Chiron's merger with Cetus Corporation in December 1991. He joined Cetus in 1987 as Senior Director of Corporate Ventures and was named Vice President and General Manager of the PCR (Polymerase Chain Reaction) Division in November 1988. Dr. Gerber is on the board of directors of Conatus Pharmaceuticals, Inc., Aviir, Inc., Nexus Dx, Inc. and Vivaldi Biosciences. Dr. Gerber earned his B.S. and M.D. degrees from the University of California, San Francisco School of Medicine.

John W. Larson has served as a member of our Board of Directors since January 1996. From 2003 until his retirement in December 2009, Mr. Larson was a partner at the law firm of Morgan, Lewis & Bockius LLP. Mr. Larson served as partner at the law firm of Brobeck, Phleger & Harrison LLP (Brobeck) from 1969 until retiring in January 2003, except for the period from July 1971 to September 1973 when he was in government service as Assistant Secretary of the United States Department of the Interior and Counselor to George P. Shultz, Chairman of the Cost of Living Council. From 1988 until March 1996, Mr. Larson was Chief Executive Officer of Brobeck. Mr. Larson serves on the board of the Needham Funds and on the boards of several privately held companies. Mr. Larson holds an L.L.B. and a B.A., with distinction, in economics, from Stanford University.

Steven Mento has served as a member of our Board of Directors since May, 2005. He is President and Chief Executive Officer of Conatus Pharmaceuticals Inc. From 1997 to 2005 he was President and CEO of Idun Pharmaceuticals and prior to that, from 1982 to 1992, Dr. Mento held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January of 1992, he joined Viagene, Inc. as Vice President of Research and Development. Dr. Mento was responsible for directing the company's transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. In October of 1995, Chiron Corporation acquired Viagene, Inc., and renamed the company Chiron Viagene, Inc. Dr. Mento served as President of Chiron Viagene, Inc. and Vice President of Chiron Corporation until August of 1997. As President, Dr. Mento had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr. Mento holds Bachelor of Arts, Master of Science, and Ph.D. degrees in microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto. Dr. Mento currently serves on the Boards of BIOCOM , the Biotechnology Organization(BIO), the BIO Health Section Governing Body, the BIO ECS Governing Body, SDSU BioScience Center Scientific Advisory Board, and Cal State San Marcos Advisory Council.

William R. Ringo has served as Chairman of our Board of Directors since April 16, 2010. From April 2008 until his retirement in April 2010, Mr. Ringo was the Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. and was responsible for guiding Pfizer’s overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which acquired Abgenix in 2006. Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. From 2001 to 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the non-executive chairman of the Board of Directors after serving as interim Chief Executive Officer from June to September 2003. Mr. Ringo serves on the Board of Directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana’s life sciences research and corporate strengths in life sciences while encouraging business development in the region. He received a B.S. in Business Administration and an M.B.A. from the University of Dayton.

Thomas G. Wiggans has served as a member of our Board of Directors since June 2008. Mr. Wiggans was Chairman and CEO of Peplin, Inc., which was acquired by LEO Pharma of Copenhagen Denmark in November 2009. Prior to joining Peplin, he served as Chief Executive Officer of Connetics Corporation, a biotechnology company, from 1994, and as Chairman of the Board from January 2006, until December 2006 when Connetics Corporation was acquired by Stiefel Laboratories. From 1992 to 1994, Mr.Wiggans served as President and Chief Operating Officer of CytoTherapeutics, a biotechnology company. From 1980 to 1992, Mr. Wiggans served in various positions at Ares-Serono Group, a pharmaceutical company, including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans currently serves as a member of the board of directors of Onyx Pharmaceuticals Inc.and Somaxon Pharmaceuticals, and the Board of Trustees of the University of Kansas Endowment Association. In addition, he is Chairman of the Biotechnology Institute, a non-profit educational organization. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

Scientific Advisory Board

Our Scientific Advisory Board is comprised of experts in molecular biology, structural biology, biophysics, biochemistry, cell biology, and gene expression and includes some of the pioneers in the field of zinc finger DNA binding protein research.

Judith Campisi, Ph.D., is Head, Center for Research and Education in Aging Life Sciences Division of the Berkeley National Laboratory, where she has been conducting aging and cancer research since 1990. From 1984 to 1990, Dr. Campisi held professorships within the Department of Biochemistry at the Boston University School of Medicine. Dr. Campisi received her Ph.D. in biochemistry and a B.A. in chemistry from the State University of New York, Stony Brook.

,Barrie Carter, Ph.D. was the Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation from 1992 until 2008. Previously, he was at the National Institutes of Health (NIH) for 22 years serving as Chief of the Laboratory of Molecular and Cellular Biology in the National Institute for Diabetes and Digestive and Kidney Diseases from 1982 to 1992. Prior to joining the NIH, he was a post-doctoral fellow at the Imperial Cancer Research Fund Laboratories in London, England. He received his B.Sc. with Honors from the University of Otago, Dunedin, New Zealand and his Ph.D. in the Biochemistry Department of the University of Otago Medical School. Dr. Carter's long-term research interests are in the molecular biology of viruses, development of AAV vectors and gene therapy. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology. From 1995-2000 Dr. Carter was an Affiliate Professor of Medicine at the University of Washington Medical School. Dr. Carter currently serves as a member of the Advisory Committee to the Director, NIH and is a member of the Board of Directors of the American Society for Gene Therapy.

Michael Gilman, Ph.D. is President and CEO of Stromedix, Inc. and most recently served as Executive Vice President of Research at Biogen Idec, Inc. During his six-year tenure at Biogen Idec, from 1999 to 2005, Dr. Gilman managed discovery research including inflammatory and autoimmune diseases, and cancer. From 1994 to 1999, Dr. Gilman served as Executive Vice President and Chief Scientific Officer of Ariad Pharmaceuticals Inc. where he was responsible for drug discovery activities to develop novel gene- and cell-regulation technologies.
Earlier in his career, Dr. Gilman was a principal investigator at Cold Spring Harbor Laboratory where he ran an active research programs in growth control and cancer, signal transduction and gene transcription and held adjunct academic appointments at SUNY Stony Brook. He earned a Ph.D. in Biochemistry from the University of California, Berkeley, and holds an S.B. in Life Sciences from the Massachusetts Institute of Technology.

Sir Aaron Klug, OM FRS is a member of the MRC Laboratory of Molecular Biology, Cambridge UK. He did much of the founding work on the structure of zinc finger DNA-binding proteins (ZFPs) and their interaction with DNA. He is the recipient of numerous honors and awards including the Nobel Prize for Chemistry. Sir Aaron was director of the MRC Laboratory of Molecular Biology from 1986-1996, and President of the Royal Society. He was a Founder and Director of Gendaq, a company founded in the United KIngdom to commercialize ZFPs and their various applications. Sangamo acquired Gendaq in 2001.

Gabor M. Rubanyi, M.D., Ph.D. is Chief Scientific Officer of Cardium Therapeutics, Inc. Prior to joining Cardium in June 2006, he was Vice President and Head of the Gene Therapy Department at Berlex Biosciences in Richmond, California and Adjunct Professor of Molecular and Cellular Physiology at the University of California at Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, he was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories, Cedar Knolls, New Jersey (1987-1990) and Associate Professor at the Mayo Clinic Medical School, Rochester, Minnesota (1983-1987). The author and co-author of 22 books and over 325 research articles, he serves as an editorial board member for several biomedical journals and is a member of numerous American and international scientific societies. He is the Founder of the biomedical journal Endothelium. His pioneering work on the nature and characterization of endothelium-derived relaxing and contracting factors contributed in a significant way to our present knowledge about endothelial control of vascular function in health and disease.

Kevin Struhl, Ph.D., is the David Wesley Gaiser Professor of Biological Chemistry in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Struhl has established many of the principles involved in the molecular mechanisms of transcriptional activation and repression in eukaryotic cells including the recruitment of gene-specific and general transcription factors as well as histone deacetylases. Dr. Struhl received his Ph.D. in biochemistry from Stanford University, and S.M. and S.B. degrees from the Massachusetts Institute of Technology.

back to top